Placebo News and Research

RSS

Research findings highlight power of expectations to drive brain activity in Parkinson's patients

Learning-related brain activity in Parkinson's patients improves as much in response to a placebo treatment as to real medication, according to a new study by researchers at the University of Colorado Boulder and Columbia University.

26 Nov 2014

Bayer's Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA

The U.S. Food and Drug Administration has granted qualified infectious disease product (QIDP) designation to two Bayer investigational agents, Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation (DPI).

24 Nov 2014

AGA's journals highlight important updates into treatments for cirrhosis, NAFLD

Cirrhosis and nonalcoholic fatty liver disease (NAFLD) are two serious liver conditions with limited pharmacological treatments. The December issues of AGA's journals -- Clinical Gastroenterology and Hepatology and Gastroenterology -- highlight important updates into treatments for these two debilitating diseases.

23 Nov 2014

Investigational drug maintains normal potassium levels in patients with chronic kidney disease

Research published today found that the investigational drug patiromer decreased high potassium levels and maintained normal potassium levels in patients with chronic kidney disease. The results of a multicenter trial appear in the New England Journal of Medicine.

21 Nov 2014

Clementia gets Orphan Medicinal Product Designation from EMA for palovarotene

Clementia Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation for palovarotene, the company's lead product candidate, for the treatment of fibrodysplasia ossificans progressiva (FOP).

21 Nov 2014

Auxilium Pharmaceuticals presents STENDRA clinical data for ED treatment at SMSNA Scientific Meeting

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that data were presented regarding the use of STENDRA® (avanafil) tablets for the treatment of erectile dysfunction (ED) at the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA) held in Miami from November 20-23, 2014.

20 Nov 2014

Omega-3 benefits may be sustained in early psychosis

The positive effects of omega-3 supplementation seen in patients at high risk of psychosis in a previous randomised, controlled trial may be sustained, the investigators reported at the International Early Psychosis Conference in Tokyo, Japan.

19 Nov 2014

Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen Research & Development, LLC today announced the submission of a New Drug Application (NDA) for three-month atypical antipsychotic paliperidone palmitate to the U.S. Food and Drug Administration. The NDA seeks approval for the medication as a treatment for schizophrenia in adults.

19 Nov 2014

Common anti-malaria medicine could have significant impact on colorectal cancer

Medical experts say a common malaria drug could have a significant impact on colorectal cancer providing a cheap adjunct to current expensive chemotherapy.

18 Nov 2014

Nonlinear correlation between axitinib dose, dBP increase

A pharmacokinetic–pharmacodynamic model shows that diastolic blood pressure rises with increasing doses of axitinib in patients with metastatic renal cell carcinoma, US researchers report, although this relationship is not linear.

18 Nov 2014

Early sodium supplementation improves weight gain in premature infants

Early sodium supplementation for very premature infants can enhance weight gain according to a recent study by researchers at the University of Cincinnati Medical Center and Cincinnati Children's Hospital Medical Center.

18 Nov 2014

New oral medication shows promise in treating fibromyalgia

A new oral medication known as IMC-1, developed by Innovative Med Concepts, proved highly effective at reducing pain and other symptoms of fibromyalgia (FM) in patients in a recent clinical trial.

18 Nov 2014

Prana's Phase 2 trial data on Huntington Disease published in The Lancet Neurology

Prana Biotechnology has today announced the results of its Phase 2 trial in Huntington Disease, REACH2HD, has been published online in one of the world’s leading medical journals, The Lancet Neurology.

18 Nov 2014

Study evaluates efficacy, safety of zirconium cyclosilicate drug in patients with hyperkalemia

Mikhail Kosiborod, M.D., of Saint Luke's Mid America Heart Institute, Kansas City, and colleagues evaluated the efficacy and safety of the drug zirconium cyclosilicate in patients with hyperkalemia (higher than normal potassium levels). The study appears in JAMA and is being released to coincide with its presentation at the American Heart Association's Scientific Sessions 2014.

18 Nov 2014

Adding ezetimibe to statin therapy reduces cardiovascular events

More than a decade ago, researchers from Brigham and Women's Hospital demonstrated that a high dose statin, which lowered cholesterol further than a regular dose statin, provided better clinical outcomes. But questions remained about whether further reducing cholesterol would be even more effective in reducing cardiovascular-related events.

18 Nov 2014

ZS Pharma reports positive ZS-9 Phase 3 clinical trial for treatment of hyperkalemia

ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today presented detailed results from HARMONIZE (ZS004) at the late-breaking Clinical Science Special Reports Session of the American Heart Association Scientific Sessions.

18 Nov 2014

NIH study finds limited kidney benefit from more rigorous blood pressure treatment

Using two drugs was no more effective than a single drug in slowing disease progression in people with autosomal dominant polycystic kidney disease (ADPKD), according to two studies funded by the National Institutes of Health. One of the studies also showed that rigorous blood pressure treatment slowed growth of kidney cysts, a marker of ADPKD, but had little effect on kidney function compared to standard blood pressure treatment.

17 Nov 2014

No survival benefit with dacomitinib in pretreated patients with advanced NSCLC

The irreversible, pan-epidermal growth factor receptor tyrosine kinase inhibitor dacomitinib does not offer a survival benefit in pretreated patients with advanced or metastatic non-small-cell lung cancer, phase III trial results show.

14 Nov 2014

Smart drug Modafinil can impair cognitive performance in healthy students

It is claimed one in five students have taken the 'smart' drug Modafinil to boost their ability to study and improve their chances of exam success.

14 Nov 2014

Oxytocin hormone inhibits fear center in brain, shows study

Frightening experiences do not quickly fade from memory. A team of researchers under the guidance of the University of Bonn Hospital has now been able to demonstrate in a study that the bonding hormone oxytocin inhibits the fear center in the brain and allows fear stimuli to subside more easily.

14 Nov 2014

Placebo News and Research

Research findings highlight power of expectations to drive brain activity in Parkinson's patients

Bayer's Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA

AGA's journals highlight important updates into treatments for cirrhosis, NAFLD

Investigational drug maintains normal potassium levels in patients with chronic kidney disease

Clementia gets Orphan Medicinal Product Designation from EMA for palovarotene

Auxilium Pharmaceuticals presents STENDRA clinical data for ED treatment at SMSNA Scientific Meeting

Omega-3 benefits may be sustained in early psychosis

Janssen announces submission of NDA for three-month paliperidone palmitate

Common anti-malaria medicine could have significant impact on colorectal cancer

Nonlinear correlation between axitinib dose, dBP increase

Early sodium supplementation improves weight gain in premature infants

New oral medication shows promise in treating fibromyalgia

Prana's Phase 2 trial data on Huntington Disease published in The Lancet Neurology

Study evaluates efficacy, safety of zirconium cyclosilicate drug in patients with hyperkalemia

Adding ezetimibe to statin therapy reduces cardiovascular events

ZS Pharma reports positive ZS-9 Phase 3 clinical trial for treatment of hyperkalemia

NIH study finds limited kidney benefit from more rigorous blood pressure treatment

No survival benefit with dacomitinib in pretreated patients with advanced NSCLC

Smart drug Modafinil can impair cognitive performance in healthy students

Oxytocin hormone inhibits fear center in brain, shows study

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News